

Date: 23/06/2016

FREEDOM OF INFORMATION REQUEST FOI/012836 – Cancer

Within your health trust how many patients are currently [within the past 6 months] being treated for head and neck cancer (Squamous cell carcinoma) ?

A: DGOH has treated 8 patients for neck and head cancer (SCC) in the last 6 months.

Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients ?

A. Locally advanced - 0

B. Recurrent and/or metastatic - 0

(note, most patients are referred to New Cross Hospital)

Of the these patients please split by their current drug treatment; - N/A

Carboplatin (Only or in combination with 5-FU)

Cetuximab (Erbix) and chemotherapy or radiotherapy

Cetuximab (Erbix) Only

Cisplatin (Only or in combination with 5-FU)

Docetaxel (Taxotere), (Only or in combination with 5-FU)

Fluorouracil (5FU)

Radiotherapy Only

Other - Specify

Does your health trust participate in any on-going clinical trials for the treatment of head and neck cancer patients, if so please could you provide details ?

A: As a Trust we do not participate in trials for the treatment of head and neck cancer patients. However, we are part of Head and Neck cancer MDT with Royal Wolverhampton Hospital Trust and our patients may get an offer to participate in trials for the treatment of head and neck cancer at Royal Wolverhampton Hospital Trust.

Within your health trust how many patients are currently [within the past 6 months] being treated for metastatic Colorectal Cancer?

A: We have treated 53 patients for metastatic colorectal cancer within the last 6 months.

Of those patients please split by their current drug treatment;

Bevacizumab: - 0

Cetuximab: - 1

Panitumumab: - 0  
Aflibercept: - 1  
Oxaliplatin: - 0  
Irinotecan: - 0  
5-Fluorouracil: - 0  
Irinotecan with 5-fluorouracil (5FU) and folinic acid [FOLFIRI]: - 26  
Oxaliplatin with 5-fluorouracil (5FU) and folinic acid [FOLFOX]: - 6  
Capecitabine and oxaliplatin (CAPOX / XELOX): - 7  
Capecitabine and irinotecan (CAPIRI): - 0  
Other –  
Irinotecan modified deGramont+ Cetuximab: - 2  
Bevacizumab + Modified deGramont: - 5  
Modified DeGramont: - 5